Recent Updates
Recently added Catalysts

High-grade Serous Ovarian Cancer: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$295Muniverse median $1.20B
Allocated capital$98M$295M competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank274/299crowding rank 275

High-grade Serous Ovarian Cancer is uncontested. Zentalis Pharmaceuticals (ZNTL) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Azenosertib in phase 2.

There is no public comparable to price it against. ZNTL spreads its $295M market cap across 3 indications, so $98M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$98M of allocated capital sits in High-grade Serous Ovarian Cancer, ranking it 274th of 299 indications by the money committed to it.

Companies developing drugs for High-grade Serous Ovarian Cancer 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ZNTLZentalis PharmaceuticalsAzenosertibPhase 21$295MNo3 23 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why High-grade Serous Ovarian Cancer counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. High-grade Serous Ovarian Cancer has one competitor and a median of $295M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

B-Cell Acute Lymphoblastic Leukemia2 companies · $92M · median $221MOrphan cornerLow-Grade Serous Ovarian Carcinoma1 company · $90M · median $723MUncontestedEndometrioid Carcinoma1 company · $90M · median $723MUncontestedRelapsed/Refractory Non-Hodgkin's Lymphoma1 company · $117M · median $351MUncontestedWell-differentiated Pancreatic Neuroendocrine Tumor1 company · $119M · median $356MUncontestedRecurrent Cutaneous T-Cell Lymphoma1 company · $119M · median $356MUncontestedAdenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma1 company · $64M · median $129MUncontestedStage IV Merkel Cell Carcinoma1 company · $134M · median $134MUncontested

High-grade Serous Ovarian Cancer pipeline questions

Which biotech companies are developing drugs for High-grade Serous Ovarian Cancer?

Zentalis Pharmaceuticals (ZNTL, Azenosertib, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in High-grade Serous Ovarian Cancer.

How advanced is the High-grade Serous Ovarian Cancer pipeline?

Of the 1 clinical-stage programme in High-grade Serous Ovarian Cancer, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for High-grade Serous Ovarian Cancer?

No. ZNTL is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in High-grade Serous Ovarian Cancer, which is why the indication is classified as uncontested.

When is the next High-grade Serous Ovarian Cancer catalyst?

The next dated catalyst in High-grade Serous Ovarian Cancer is ZNTL on 23 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map